| December 2018 |
| 20 Dec |
Meetings conducted with Institutional Investors/Research Analysts |
 |
| 19 Dec |
Meetings conducted with Institutional Investors/Research Analysts |
|
| 10 Dec |
Meetings conducted with Institutional Investors/Research Analysts |
|
| 03 Dec |
Change in name of Registrar & Share Transfer Agent- Karvy Computershare Private Limited to Karvy Fintech Private Limited |
|
| November 2018 |
| 30 Nov |
Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU |
|
| 27 Nov |
Meetings conducted with Institutional Investors/Research Analysts. |
|
| 26 Nov |
Change in the name & contact details of Key Managerial Personnel under the Policy for Determination of Materiality of disclosures |
|
| 23 Nov |
Meetings conducted with Institutional Investors/Research Analysts. |
|
| 21 Nov |
Meetings conducted with Institutional Investors/Research Analysts. |
|
| 16 Nov |
Investor Presentation for Quarter ended September 30, 2018 |
|
| 16 Nov |
Meetings conducted on November 16, 2018 with Institutional Investors/Research Analysts. |
|
| 15 Nov |
Meetings conducted with Institutional Investors/Research Analysts. |
|
| 12 Nov |
Meetings conducted on November 12, 2018 with Institutional Investors/Research Analysts. |
|
| 12 Nov |
Biocon's Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations |
|
| 9 Nov |
Meetings conducted on November 8, 2018 and November 9, 2018 with Institutional Investors/Research Analysts. |
|
| October 2018 |
| 25 Oct |
Biocon Q2FY19 Earnings PressRelease |
|
| 19 Oct |
Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab |
|
| 08 Oct |
Intimation of Board Meeting scheduled on Thursday, October 25, 2018. |
|
| September 2018 |
| 27 Sep |
Meetings conducted on September 26, 2018 and September 27, 2018, with Institutional Investors/Research Analysts. |
|
| 22 Sep |
Biocon’s Drug Substance Facility in Bangalore completes US FDA inspection with no observations |
|
| 21 Sep |
Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim - Press Release |
|
| 20 Sep |
Meetings conducted on September 19, 2018 and September 20, 2018, with Institutional Investors/Research Analysts |
|
| 11 Sep |
Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015. |
|
| 11 Sep |
Meetings conducted on September 10, 2018, with Institutional Investors/Research Analysts |
|
| 10 Sep |
Meetings conducted on September 07, 2018, with Institutional Investors/Research Analysts |
|
| 07 Sep |
Meetings conducted on September 06, 2018, with Institutional Investors/Research Analysts. |
|
| 06 Sep |
Meetings conducted on September 05, 2018, with Institutional Investors/Research Analysts |
|
| 05 Sep |
Meetings conducted on September 04, 2018, with Institutional Investors/Research Analysts |
|
| 03 Sep |
Appointment of Key Managerial Personnel |
|
| 03 Sep |
Investor Presentation Announcement for Quarter ended June 30, 2018 |
|
| August 2018 |
| 28 Aug |
Meeting and teleconference conducted on August 27, 2018 and on August 28, 2018 respectively, with Institutional Investors/Research Analysts |
|
| 23 Aug |
Meeting and teleconference conducted on August 23, 2018 with Institutional Investors/Research Analysts |
|
| 16 Aug |
Meeting conducted on August 15, 2018 with Institutional Investors/Research Analysts |
|
| 14 Aug |
Meeting conducted on August 13, 2018 with Institutional Investors/Research Analysts |
|
| 09 Aug |
Meeting conducted on August 08, 2018 with Institutional Investors/Research Analysts |
|
| 06 Aug |
Meeting conducted on August 06, 2018 with Investors/Research Analysts |
|
| 03 Aug |
Teleconference conducted on August 03, 2018 with Investors/Research Analysts |
|
| 01 Aug |
Teleconference conducted on July 31, 2018 with Investors/Research Analysts |
|
| July 2018 |
| 28 July |
Announcement on appointment of Mr. Bobby Kanubhai Parikh as Independent Director |
|
| 28 July |
Proceedings of Annual General Meeting including Voting Results and Scrutinizer’s Report |
|
| 26 July |
Audited Financial Results (Standalone and consolidated) for Q1FY19 |
|
| 26 July |
Outcome of the Board Meeting held on 26 July 2018 |
|
| 26 July |
Biocon Q1FY19 Earnings PressRelease |
|
| 05 July |
Intimation of Board Meeting for approving unaudited Q1 financials |
|
| 04 July |
Company Statement: Biocon's Sterile Drug Product facility receives EU GMP Certification |
|
| June 2018 |
| 27 June |
Intimation regarding Meeting with Investor |
|
| 23 June |
Biocon’s Sterile Drug Product facility Receives EIR from USFDA |
|
| 22 June |
Intimation regarding Teleconference with Investor |
|
| 05 June |
Meeting conducted on 4th & 5th of June 2018 with Institutional Investors/Research Analysts. |
|
| 05 June |
U.S. FDA approves Mylan and Biocon's FulphilaTM (pegfilgrastim-jmdb), the first Biosimilar to Neulasta |
|
| 04 June |
Tata Memorial Hospital team presents Biocon’s Nimotuzumab study results at American Society of Clinical Oncology (ASCO) Annual Meeting 2018 |
|
| 02 June |
Biocon and Mylan Press Release pertaining to presenting new data to American society of Clinical Oncology (ASCO) |
|
| May 2018 |
| 18 May |
SAST Regulation 29(2) |
|
| 18 May |
Intimation regarding Sale of Equity Shares of the Syngene International Limited |
|
| 15 May |
Intimation regarding Analysts/ Institutional Investors meet |
|
| 09 May |
Intimation regarding Analysts/ Institutional Investors meet |
|
| 08 May |
Intimation regarding Analysts/ Institutional Investors meet |
|
| 02 May |
Meeting / teleconference conducted on 1st and 2nd of May 2018 with In stitutional Investors / Research Analysts. |
|
| 02 May |
Company Statement on Biocon Regulatory Audit Update
|
|
| April 2018 |
| 26 April |
Audited Financial Results (Standalone and consolidated) for the quarter and year ended 2017-18 |
|
|
| 26 April |
Outcome of the board meeting held on 26th April, 2018 |
|
|
| 26 April |
Press Release for the quater and financial year ended 2017-18 |
|
|
| 16 April |
Proposal to consider recommendation of final dividend |
|
|
| 11 April |
Company Statement: Mylan and Biocon seek to accelerate introduction of Adalimumab biosimilar in EU |
|
|
| 05 April |
Intimation of Board Meeting Ref: Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
|
|
| March 2018 |
| 28 Mar |
Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine |
|
|
| 27 Mar |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 20 Mar |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 16 Mar |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 15 Mar |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 14 Mar |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 13 Mar |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 02 Mar |
Intimation regarding change in Compliance Officer under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015. |
|
|
| 02 Mar |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| February 2018 |
| 27 Feb |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 22 Feb |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 21 Feb |
Company Statement on US-FDA Inspection at Biocon Malaysia |
|
|
| 20 Feb |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 15 Feb |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 08 Feb |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 08 Feb |
Intimation regarding Analysts/ Institutional Investors meet |
|
|
| 06 Feb |
Intimation regarding Analysts/Institutional Investors Meet |
|
|
| 05 Feb |
Analysts/Institutional Investors Presentation |
|
|
| 02 Feb |
Intimation regarding Analysts/Institutional Investors Meet |
|
|
| January 2018 |
| 30 Jan |
Intimation regarding Analysts/Institutional Investors Meet |
|
|
| 29 Jan |
Intimation regarding Analysts/Institutional Investors Meet |
|
|
| 29 Jan |
Press Release Media Release |
|
|
| 29 Jan |
Biocon Insider Trading Code 2015 - Amended on Jan 24, 2018 |
|
|
| 24 Jan |
Biocon Document Retention and Archival Policy - Amended on Jan 24, 2018 |
|
|
| 24 Jan |
|
|
| 23 Jan |
Intimation under Regulation 30 of SEBI Regulations, 2015 |
|
|
| 18 Jan |
Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars |
|
|
